ECM
ORMP icon

ExodusPoint Capital Management’s Oramed Pharmaceuticals ORMP Stock Holding History

ExodusPoint Capital Management’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-18,325
Closed -$159K – 2305
2022
Q1 		$159K Buy
+18,325
New +$188K ﹤0.01% 1951
2021
Q2 		– Sell
-52,486
Closed -$533K – 2679
2021
Q1 		$533K Buy
+52,486
New +$431K 0.01% 1302

Other funds holding ORMP

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
JSMC
Jess S. Morgan & Co Los Angeles, California $115M AUM 16.65% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ExodusPoint Capital Management's ORMP Position: Q2 2022 in Review

ExodusPoint Capital Management sold out of Oramed Pharmaceuticals (ORMP) in Q2 2022, closing a stake of 18,325 shares — an estimated $159K sold.

ExodusPoint Capital Management first reported a position in ORMP in Q1 2021 and held it in 2 quarters. The position peaked at $533K in Q1 2021. 88 funds tracked by Wall St. Rank hold ORMP as of Q2 2022.

  • ExodusPoint Capital Management reported no remaining Oramed Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • ExodusPoint Capital Management sold 18,325 Oramed Pharmaceuticals shares in Q2 2022, an estimated $159K.
  • ExodusPoint Capital Management first reported a position in Oramed Pharmaceuticals in Q1 2021 and held it in 2 quarters.
  • ExodusPoint Capital Management's Oramed Pharmaceuticals position peaked at $533K in Q1 2021.
  • 88 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q2 2022.

Based on ExodusPoint Capital Management's 13F filing for Q2 2022, filed 22 Aug 2022.